SS Innovations International, Inc. SSII

SS Innovations International reported a new robotic cardiac surgery program at HCG Hospital in Mithakhali, Ahmedabad, using the SSi Mantra 3.0 system for a LIMA takedown led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik. The company cited 238 SSi Mantra systems installed as of September 8, up 42% from end-2025, across 12 countries with recent additions in Colombia, Sri Lanka and the Philippines. SS Innovations is pursuing U.S. FDA review and EU CE marking to expand Mantra into additional international markets. Expansion momentum and ongoing regulatory pursuit imply meaningful upside, contingent on regulatory approvals.

SS Innovations International (SSII) expands global footprint as SSi Mantra procedures reach 14,103. Milestone procedure volumes combined with international expansion indicate major adoption gains that can significantly lift revenue trajectory and investor sentiment.

SS Innovations International, Inc. introduces robotic cardiac surgery to Sri Lanka. Geographic expansion into Sri Lanka supports SSII revenue growth via new market access.

SS Innovations International reports 79% growth in SSi Mantra procedures and expands global reach. Strong procedure growth combined with international expansion signals major gains in adoption and revenue trajectory.

SS Innovations International, Inc. updated on its continuing progress and achievement of multiple milestones. Progress updates can moderately influence company trajectory and market performance.

SS Innovations International is leveraging India's surgical robotics market opportunity to drive its global expansion and growth. Focus on surgical robotics expansion in India signals major strategic positioning with potential to significantly boost SSII's market trajectory.

SS Innovations International (SSII) records growth in Indian surgical robotics that signals expanded market opportunities. Indian surgical robotics growth expands SSII market reach and competitive positioning.

SS Innovations International (SSII) posted record Q2 revenue, indicating sustained commercial momentum for its SSi Mantra robotic surgery platform. Record quarterly revenue confirms accelerating adoption of the core SSi Mantra system and strengthens the company's growth trajectory.

SS Innovations International (SSII) reports record Q2 revenue of $13.9M, up 39.4%. Record revenue growth points to accelerating commercial traction likely to lift valuation and sentiment.

SS Innovations International, Inc. (SSII) reported its second quarter 2026 financial results. Quarterly financial results provide performance updates that may influence short-term market views but rarely shift long-term company trajectory.

SS Innovations International (SSII) expands its global footprint in the fast-growing robotic surgery market. Global expansion in robotic surgery positions SSII for substantial growth and stronger competitive positioning.

SS Innovations International (SSII) strengthens leadership as global robotic surgery expansion gains pace. Leadership strengthening supports accelerating global robotic surgery expansion at SS Innovations International (SSII).

SS Innovations International (SSII) CEO presents strategy to expand affordable robotic surgery access and adoption. CEO strategy for affordable robotic surgery expansion signals major growth opportunity and competitive repositioning for SSII.

SS Innovations International subsidiary graduates first cardiac robotic surgery training class. First training class graduation marks incremental progress toward wider adoption of SSII robotic systems.

SS Innovations subsidiary SSICRS graduates its inaugural cardiac robotic surgery training class. First graduating class advances SSII robotic surgery training and potential system adoption.

SS Innovations International, Inc. (SSII) wins 2026 Surgical Robotics Industry Outstanding Company Award. Industry award win moderately strengthens SSII competitive positioning and market sentiment in surgical robotics.

SS Innovations completed world’s longest-distance robotic telesurgery. Longest-distance telesurgery demonstrates core robotic technology leadership with potential to drive adoption and valuation.

SS Innovations International, Inc. (SSII) reported first quarter 2026 financial results. Quarterly financial results disclosure typically drives significant shifts in investor sentiment and stock performance for SSII.

SS Innovations International, Inc. (SSII) demonstrated long-distance telesurgery capabilities at the Royal Australian College of Surgeons Annual Scientific Congress. Showcasing advanced telesurgery at a prestigious surgical congress positions SSII as a leader in robotic surgery innovation, boosting market visibility and growth potential.

SS Innovations International, Inc. (SSII) has surpassed 10,500 surgeries performed with its SSi Mantra Surgical Robotic System, highlighting strong adoption and clinical success of the platform. Surpassing 10,500 surgeries marks a major milestone in product utilization, signaling robust market traction and potential for accelerated revenue growth.

SS Innovations International, Inc. (SSII) unveiled cutting-edge surgical robotic technologies at SMRSC 2026. Unveiling cutting-edge surgical robotics at a major conference highlights SSII's innovation leadership, poised to drive market growth and investor confidence.

SS Innovations International, Inc. (SSII) will host SMRSC 2026 in New Delhi, India, from April 9-11, 2026. Hosting a prominent industry conference elevates SSII's global leadership and visibility, potentially accelerating partnerships and market expansion.

SS Innovations International, Inc. (SSII) secures regulatory approvals for its SSi Mantra surgical robot in key emerging markets, enabling market entry and expansion. Regulatory approvals in key emerging markets facilitate SSII's international growth and revenue potential for SSi Mantra.

SS Innovations International, Inc. (SSII) gains regulatory approvals for its SSi Mantra Surgical Robotic System in Colombia, Oman, Sri Lanka, and Kenya, enabling global expansion and new market opportunities. Regulatory approvals in four countries open new international markets for SSII's robotic surgery system, boosting revenue potential and competitive positioning.

SS Innovations International, Inc. (SSII) advances telesurgery with XCath robot successfully treating stroke patient remotely. XCath robot's remote stroke treatment demonstrates breakthrough telesurgery capability, positioning SSII for significant growth in medtech and positive market sentiment.

SS Innovations International, Inc. (SSII) shares rose 10.8% after a telesurgery milestone, despite auditor raising going concern doubts. Telesurgery milestone drove significant stock gains amid serious auditor financial viability concerns.

SS Innovations International, Inc. (SSII) secured approval for its SSi Mantra Surgical Robotic System to perform telesurgeries in Indonesia and the Philippines, enabling remote surgeries and expanding market access in Southeast Asia. Approval for telesurgeries in Indonesia and Philippines represents a major regulatory milestone that boosts SSII's international expansion and revenue potential in emerging markets.

SS Innovations International, Inc. (SSII) reported fourth quarter and full year 2025 financial results. Q4 and full-year financial results directly affect SSII's financial performance, investor sentiment, and stock trajectory.

SS Innovations International, Inc. (SSII) raised $18.6 million in funding as its surgical robot nears US market entry. Raising $18.6M funds commercialization of a surgical robot nearing US launch, significantly enhancing SSII's growth and competitive edge.

SS Innovations International, Inc. (SSII) completed an $18.6 million private placement to fund growth initiatives. Securing $18.6 million in funding directly enables expansion and growth, significantly enhancing SSII's strategic position and market performance.